Candel Therapeutics At A Glance

Founded: 2003 (In 2019 the company operated as Advantagene, Inc. doing business as Candel Therapeutics. As of 1 December 2020, the company’s name is Candel Therapeutics.

Location: Needham, Massachusetts

Employees: ~40

R&D Focus: oncolytic virus-based immunotherapy for solid tumors

Management Team: President and CEO, Paul Peter Tak; CSO and founder, Estuardo Aguilar-Cordova; Chief Medical Officer, Laura Aguilar; CFO, John Canepa; Chief Business Officer, Nathan Caffo; Chief Regulatory Officer, Susan Stewart

Financing: $65.4m in series A, B and C in 2016 and 2019

Investors: PBM Capital Group, Northpond Ventures, Sands Capital Ventures, H7 Holdings, Level One Partners

Candel Aims High In Next Stage Of Cancer Immunotherapy Mission

More from Emerging Company Profiles

More from Start-Ups & SMEs